Zacks Bull and Bear of the Day Highlights: Eastman Chemical, Kirkland's …Sacramento BeeMeanwhile, Biogen and partner Abbott (NYSE:ABT) moved their MS candidate, daclizumab, into a two-year phase III study (DECIDE) in July 2010. Daclizumab is bein…
Zacks Bull and Bear of the Day Highlights: Eastman Chemical, Kirkland's …PR Newswire (press release)Meanwhile, Biogen and partner Abbott (NYSE: ABT) moved their MS candidate, daclizumab, into a two-year phase III study (DECIDE) in July 2010. Dacl…
Zacks Bull and Bear of the Day Highlights: Eastman Chemical, Kirkland's …NASDAQMeanwhile, Biogen and partner Abbott ( ABT ) moved their MS candidate, daclizumab, into a two-year phase III study (DECIDE) in July 2010. Daclizumab is being evaluated…
Zacks Bull and Bear of the Day Highlights: Eastman Chemical, Kirkland's …InvestorIdeas.com (press release)Meanwhile, Biogen and partner Abbott (ABT – Analyst Report) moved their MS candidate, daclizumab, into a two-year phase III study (DECIDE) i…
Zacks Bull and Bear of the Day Highlights: Eastman Chemical, Kirkland's …Zacks.comMeanwhile, Biogen and partner Abbott (ABT – Analyst Report) moved their MS candidate, daclizumab, into a two-year phase III study (DECIDE) in July 2010. Daclizumab …
Standard Review for Biogen's BG-12 – Analyst BlogNASDAQMeanwhile, Biogen and partner Abbott ( ABT ) moved their MS candidate, daclizumab, into a two-year phase III study (DECIDE) in July 2010. Daclizumab is being evaluated as a once-monthly or bi-w…
Standard Review for Biogen's BG-12Zacks.comMeanwhile, Biogen and partner Abbott (ABT – Analyst Report) moved their MS candidate, daclizumab, into a two-year phase III study (DECIDE) in July 2010. Daclizumab is being evaluated as a once-monthly or b…
The Deal PipelineAbbott continues to prep for new focusThe Deal PipelineIt has also supplemented its pipeline through additional partnerships over the past few years, forging deals with Reata, Biogen Idec Inc. (daclizumab for multiple sclerosis) and Br…
Pharmazeutische Zeitung onlineNebenwirkung DiabetesPharmazeutische Zeitung onlineDazu gehören der mTOR-Inhibitor Sirolimus und der monoklonale Antikörper Basiliximab, der sich gegen Interleukin-2 richtet. Behandelt wird ein Posttransplantationsdiabet…
Mass High TechBiogen Idec's CEO Discusses Q1 2012 Results – Earnings Call TranscriptSeeking AlphaAt the American Academy of Neurology meeting lastly, our pipeline was the subject of 49 platform presentations and posters, including new data for TYSA…